Key result
Drug-eluting balloons offer a novel CAD strategy, with trials expanding into complex lesion subsets.
Why the study?
Long-term safety outcomes and persistent restenosis in complex lesion subsets remain concerns despite DES use, prompting exploration of DEB as a novel treatment strategy.
The technology of percutaneous coronary intervention for atherosclerotic coronary artery disease has evolved considerably since its inception. Though Drug-Eluting Stent (DES) reduces the rate of restenosis, long-term safety outcomes and persistent restenosis in complex lesion subset remain area of concern. Recently, Drug-Eluting Balloon (DEB) represents a novel treatment strategy for atherosclerotic coronary artery disease. DEB demonstrated its added value in preclinical studies. Inspired by these results, several clinical trials particularly in complex lesion subsets have been started to explore the value of this novel treatment strategy in a broader range of lesions. This review would summarise material compositions and different characteristics and clinical outcomes of currently available DEB.
No takes yet. Share an insight, caveat, or question.
A 2017 study conducted a review in Atherosclerotic coronary artery disease. Drug-Eluting Balloon (DEB) was evaluated. Drug-eluting balloons represent a novel treatment strategy for atherosclerotic coronary artery disease, with clinical trials ongoing to explore their value in complex and broader lesion subsets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: